1

CURRICULUM VITAE ET STUDIORUM NAME

Andrea Mancuso Petricca, MD DOB: 26/04/1972 POB: Rome – Italy

PRESENT TITLE AND AFFILIATION

Oncologist Physician, Specific Research Area: Translational and Clinical Research, Expertise in Gastrointestinal / Thorax and Head & Neck Oncological Diseases, Medical Oncology Dept. directed by Cora N. Sternberg, MD, FACP, San Camillo/Forlanini Hospital, Rome, Italy, July 2005-Present

CITIZENSHIP Italian HOME ADDRESS

Via Leopoldo Nobili, 11 00146 Roma, Italy Telephone: +39-06-45422025; mobile: +39-349-1848283 or +39-393-4572121

OFFICE ADDRESS

Medical Oncology Dept San Camillo/Forlanini Hospital, Rome, Italy. 00152, Circonvallazione Gianicolense, 87 Telephone: +39-06-58704339 or +39-06-58704580 Fax: +39-06-58704317 or 39-06-58704581 e-mail: mancusoan@gmail.com

EDUCATION Degree-Granting Education University “La Sapienza”, Rome, Italy (M.D. with honours), 1998

Scientific Liceum “Teresa Gullace Talotta”, Rome, Italy (High School Diploma) 1992 Postgraduate Training

Masterclass in Leadership and Clinical Organization, Health Care Delivery Science Program, Dartmouth College, Boston, USA, 2010 ESMO Second Masterclass for Young Medical Oncologists: “Guidelines to publish high quality papers”, 4-5 June 2005, Budapest, Hungary

2

Ligue Suisse contre le cancer course: « Physician-Patient communication in cancer care » Certification with honors, March 2005 - July 2005

Fellowship, Medical Oncology, University “La Sapienza”, Rome, Italy, Oncology Certification with honors, November 1998 - November 2003 Medical Oncology Course, National Academy of Medicine, S. Eugenio Hospital, Rome, Italy, Certification with honors, November 1997 - July 1998

Training Specific Courses

ASCO University CME in Gastrointestinal and lung Tumors 2003-present Master in Gastrointestinal Cancers: Standard treatments and biologic approaches, Beth Israel Medical Centre, New York, December, 2006 Methods in Clinical Cancer Research, 7th Intensive Workshop for European Junior Clinical Oncologists, Federation of European Cancer Societies (FECS), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), June 18-24, 2005, Flims, Switzerland New drugs in Oncology: from laboratory to clinic trial. Certification of European School of Oncology, February 16-18, 2005, Bellinzona, Switzerland The Biological Bases of new target therapies in medical oncology. Rome, National Academy of Medicine, March 26-27, 2004 Change from laboratory to clinic trial: The Swedish (Karolinska Hospital) and Italian experience. University of Turin, Le Molinette Hospital, May 19-23, 2003 High School GISCAD on Colorectal Cancer, Verona, October, 2010

EXPERIENCE/SERVICE

Oncologist Physician, Specific Research Area: Translational and Clinical Research, Medical Oncology Dept. directed by Cora N. Sternberg, MD, FACP, San Camillo/Forlanini Hospital, Rome, Italy, July 2005-Present Attending as Oncologist Physician, Specific Research Area: Translational and Clinical Research, Medical Oncology Dept. directed by Franco Cavalli, MD, Istituto Oncologico della Svizzera Italiana (IOSI). Grant: European School of Oncology Foundation -ESOF-, September 2004 – July 2006

Attending as Oncologist Physician, Medical Oncology Dept. directed by Cora N. Sternberg, MD, FACP, San Camillo/Forlanini Hospital, Rome, March 2004 – September 2004

3

Consultant Medical Oncology “Madre Giuseppina Vannini” Hospital February 2004 – March 2004 Attending Medical Doctor of 5th Pneumo-Oncology Unit Department of Respiratory Diseases, San Camillo/Forlanini Hospital, Rome, Italy, February 2003 – February 2004

Attending Medical Researcher in laboratory of Gastrointestinal and Thoracic Head and Neck Medical Oncology Dpt of MD Anderson Cancer Center, Houston, Texas, USA, November 2001 – February 2003

Second Lieutenant Medical Officer attached to the First Aid Station of the First level infirmary of the 46° Air Brigate, Pisa Military Airport, January 2000 – March 2001

Medical Oncology Fellow, Department of Experimental Medicine and Pathology, University “La Sapienza”, Rome, Italy, November 1998 - November 2003

Attending Medical Student of the Oncology Dpt, Ospedale S.Eugenio, Rome, Italy, January 1998 – July 1998

Attending Medical Student of the Oncology Dpt, Policlinico Umberto I, University “La Sapienza”, Rome, Italy, November 1996 – July 1998

Attending Medical Student of the Medical Emergency Department of Policlinico Umberto I, University of Rome "La Sapienza", Rome, Italy, November 1994 – November 1996

Attending Medical Student of Department of General Pathology of Policlinico Umberto I, University “La Sapienza”, Rome, Italy, April 1994 – November 1994

MERIT AWARDS

- Winner as Senior Researcher in Immuno-oncology, Center of Excellence for Cancer Treatment and Immunotherapy Research (CECTIR), Sukumvit Hospital, Bangkok (NCI, Thailand), July 2016 – July 2019

- Grant (1000 €) to take part in EORTC-NCI-ASCO meeting (ENASCO, 2007) - Grant (25.000 $) – American-Italian Cancer Foundation, International Fellowship Program to develop a Phase Ib Pharmacokinetic and Pharmacodynamic Trial with SUTENT (SU11248) and Capecitabine in Cytokine Refractory Renal Cell Carcinoma, February 2006 - Grant (24.000 €) - scholarship - for 1 year to work in the field of methodology of biologic clinical trials in Bellinzona, Switzerland, Istituto Oncologico della Svizzera Italiana (IOSI), European School of Oncology Foundation -ESOF-, September 2004 – July 2005

4

- Grant (1000 €) to take part in 7th Intensive Workshop for European Junior Clinical Oncologists, Methods in Clinical Cancer Research, Federation of European Cancer Societies (FECS), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), June 18-24, 2005, Flims, Switzerland - Travel grant (1000 €) to take part in EORTC Groups Annual Meeting (EGAM), March 2005, Bruxelles, Belgium - Grant (600 €) as young oncologist (under 35 years old) to have published during 2004 a paper as first name on a high impact factor international oncological journal, “Fondazione Federico Calabresi”, December 2004, Genova, Italy - AIOM travel grant (500 €) for the best abstract published at VII° National AIOM Congress, Milan, November 18-21, 2006 - AIOM Travel grant (1000 €) to take part in ESMO Conference (Lugano, Switzerland, July, 5/8, 2007) as young investigator selected for oral presentation - ESMO Travel grant (1000 €) to take part in ESMO Conference (Lugano, Switzerland, July, 3/6, 2008) as young oncologist chair in genitourinary session

CONSULTANTSHIPS

- Janssen-Cilag, SpA (2004-2005) - Astellas Pharma Europe Ltd (2008-Present) - Mundipharma Pharmaceutica, July, 2008 - Merck Serono, January, 2010 - Amgen/Dompè, january 2010-present

JOURNAL REVIEWER - Annals of Oncology - British Journal Urology - Future Drugs - Lung Cancer RESEARCH

Funded Protocols

Co-investigator, “Clinical randomized phase II study UFT/LV per os vs 5FU/LV in the treatment of metastatic colo-rectal cancer” Bristol Myers-Squibb SPA, File:UFT/99-99.001 Co-investigator, “ The International Tirazone Triple Trial (i3T): A Phase III, Randomized Efficacy and Safety Study of the Combination Chemotherapy with Tirapazamine + Cisplatin +

5

Vinorelbine versus Cisplatin + Vinorelbine in Subjects with Inoperable, Previously Untreated, NSCLC” Sanofi-Synthelabo i3T EFC 3675, University “La Sapienza”, Rome, 2001 Co-investigator, “A Multistep Randomized Phase II/III Trial Comparing Oxaliplatin-5-Fluorouracil (5-FU) to Vinorelbine-5-FU in Patients with Advanced/Metastatic Breast Cancer (MBC) after Taxane/Anthracycline-Failure” DEB-99-OXA-02, University “La Sapienza”, Rome, 2002-2003 Co-investigator, "Hemoglobin levels and quality of life in patients with solid tumors treated with chemotherapy and Epoetin alfa 40K (40000 IU) once a week”. Ortho Biotech, File:OBI/EPO-ITA-01/1, University “La Sapienza”, Rome, 2002-2003 Co-investigator, “Induction treatment with Epoetin alfa 40K (40000 IU) in anemic patients treated with chemotherapy”. F.A.S.T. study (Fast Anemia Solution Treatment), Ortho Biotech, File:OBI/EPO-ITA-02/3, San Camillo/Forlanini Hospitals, University “La Sapienza”, Rome, 2003 Co-investigator, “A randomized, double blind, placebo-controlled, phase III study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK 222584 or placebo in patients with previously treated metastatic adenocarcinoma of the colon or rectum” Novartis/Schering, Protocol N° CPTK787 0133/304946, San Camillo/Forlanini Hospitals, Rome, 2004 Co-investigator, “A Phase III Randomized multicenter study of Oxaliplatin plus Pemetrexed every three weeks as first line treatment in patients with advanced and measurable Gastric cancer”, San Camillo/Forlanini Hospitals, Rome, 2004 Co-investigator, “Randomized phase III comparing immediate versus deferred chemotherapy after radical Cystectomy with pT3, pT4 and/or N+M0 transitional Carcinoma (TCC) of the bladder”, San Camillo/Forlanini Hospitals, Rome, 2004

Funded Protocols with Translational Research A Phase III Randomized, Open-Label, Multicenter Study of Taxotere every three weeks versus Taxotere plus Oblimersen one week infusion every three weeks as first line treatment in patients with Hormone Refractory prostate cancer” (EORTC 30021), San Camillo/Forlanini Hospitals, Rome, 2004 Co-investigator, “A multi-center, non-randomized, open label dose finding phase I Study with AVE8062 administered as a 30 minute intravenous infusion every 3 weeks in patients with advanced solid tumors”. (AVE8062A/1002), Ospedale San Giovanni, IOSI, Bellinzona, 2005 Co-investigator, “A Phase Ib pharmacokinetic and pharmacodynamic study to define the Optimal Dose for Combining the mTor Inhibitor AP23573 with Capecitabine (CAPE)”. (AP23573-04-105, S045AP2302), Ospedale San Giovanni, IOSI, Bellinzona, 2005

6

Co-investigator, “A Phase Ib pharmacokinetic and pharmacodynamic study to define the Optimal Dose for Combining the mTor Inhibitor AP23573 with Paclitaxel (PTX)”. (AP23573-04-104, S045AP2301), Ospedale San Giovanni, IOSI, Bellinzona, 2005 Co-investigator, “Dose finding, safety, pharmacokinetic and pharmacodynamic study of the vascular targeting agent ExherinTM administered once weekly by intravenous infusion in patients with incurable solid tumors”. (AHX-01-004/SENDO Protocol S045EXHE01), Ospedale San Giovanni, IOSI, Bellinzona, 2005 Co-investigator, “Open, uncontrolled, multicenter, phase II study of ErbituxTM (Cetuximab) in combination with Irinotecan in patients with metastatic colorectal carcinoma expressing the epidermal growth factor receptor and having progressed on a defined Irinotecan-based regimen as most recent treatment” (Mabel Study, EMR 62202-501), Ospedale San Giovanni, IOSI, Bellinzona, 2004/2005 Co-investigator, “A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma”. (EMR 62 202-025), Ospedale San Giovanni, IOSI, Bellinzona, 2005 Co-investigator, “A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination with Either Intermittent Capecitabine Plus Oxaliplatin (Xelox) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (Folfox-4) versus Folfox-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma”. (Protocol AVANT, BO17920), Ospedale San Giovanni, IOSI, Bellinzona, 2005 Co-investigator Protocol SAKK 41/04: “Capecitabine and Oxaliplatin alone or in combination with Cetuximab as first-line treatment for metastatic EGFR-positive colorectal cancer: A Randomized multicenter phase II trial”, Ospedale San Giovanni, IOSI, Bellinzona, 2005 Co-investigator, A Phase III Randomized, multicenter study of Interferon alfa versus SU11248 as First line treatment in patients with advanced renal cancer, San Camillo/Forlanini Hospitals, Rome, 2005/2006 Co-investigator, A Phase III Randomized study of SU11248 in patients with previously treated renal cancer, San Camillo/Forlanini Hospitals, Rome, 2006 Co-investigator, A Phase II Randomized, Double-blinded, multicenter Study of Satraplatin plus Prednisone, versus Placebo plus Prednisone as second line treatment in patients with Hormone Refracotry Prostate Cancer, San Camillo/Forlanini Hospitals, Rome, 2005/2006 Co-Principal Investigator Protocol SAT1-05-01: “A phase I open-label study of Gemcitabine in combination with Satraplatin in Patients with Advanced Solid Tumors” San Camillo/Forlanini Hospitals, Rome, 2006/2007

7

Co-Principal Investigator Protocol: “Phase II Study of Sorafenib (BAY 43-9006) in Patients with Renal Cell Carcinoma (RCC) who have been Previously Treated with Anti-Angiogenic Treatment”, San Camillo/Forlanini Hospitals, Rome, 2007-2010 Principal Investigator, Protocollo TAILORaifa, (Tarceva Italian Lung Optimization tRial) – Optimization of erlotinib for the treatment of patient with advanced non-small cell lung cancer: an italian randomized trial, 2008-Present Principal investigator, GISCAD Randomized Trial TOSCA, Folfox-4 (3 versus 6 months) as adjuvant chemotherapy in high risk colon cancer patients, 2008-Present A Multicenter, Randomized, Open-label Phase 3 Study of Encorafenib + Cetuximab +/- Binimetinib vs. Irinotecan + Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer, Rome 2015 A 12-week Double Blind, Placebo Controlled, Randomised Pilot Study Assessing Safety and Tolerability of Nutrifriend Cachexia in Patients Diagnosed with Non-Small Cell Lung Cancer (NSCLC) with Involuntary Weight Loss, Rome 2016 EORTC 1418-GITCG Nintedanib plus mFOLFOX for previously untreated metastatic esophagogastric adenocarcinoma: a randomized, placebo-controlled, double-blind phase II study of the EORTC GI group, Rome 2016

Other Research Activities

Co-investigator, “Study on adiuvant treatment of operable high risk breast carcinoma with Epirubicin, Docetaxel and high doses chemotherapy”, University “La Sapienza”, Rome, 1998 Co-investigator, “Drug utilization review team in Oncology, D.U.R.T.O.” Breast Cancer Care Project, University “La Sapienza”, Rome, 1999 Co-investigator, “Study on chemo-hormonal therapy of low-medium risk breast carcinoma with 0-3 metastatic lymphonodes. (Studio Impact B01), University “La Sapienza”, Rome, 1999 Co-investigator, “Controlled clinical phase III study Mig-5 (Mammella Intergruppo-5): Epirubicin + Paclitaxel vs standard chemotherapy with Cyclophosphamide, Epirubicin and 5-Fluorouracile (CEF) in adiuvant treatment of breast cancer patients with metastatic axillary lymphnodes”, University “La Sapienza”, Rome, 1999-2000 Co-investigator, ”Intermittence chemotherapy vs continuative chemotherapy in first line treatment of advanced colorectal cancer: a G.I.S.C.A.D (Gruppo Italiano per lo Studio dei carcinomi dell’Apparato Digerente) Pragmatic Phase III Study”, University “La Sapienza”, Rome, 2001-2003

8

Co-investigator, “Phase I/II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer: The Feasibility of a New Biweekly Schedule”, San Camillo/Forlanini Hospitals, University “La Sapienza”, Rome, 2003

Co-investigator, “Locally Advanced Gastric Cancer: Neoadjuvant chemotherapy with Docetaxel and Oxaliplatin in a multidisciplinary radio/surgical approach”, University “La Sapienza”, Rome, 2002 Co-investigator, “Impact of Third Line ZD 1839 therapy on Patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens” (Astra Zeneca Expanded Access Programme), University “La Sapienza”, Rome, 2003 Co-investigator, “Prevention of Oxaliplatin-induced peripheral sensory neuropathy by means of Epoetin alfa in patients with advanced colorectal cancer: an observational study”, University “La Sapienza”, Rome, 2003 Principal Investigator: Inhibition of metastatic clear cell renal carcinomas by the combined use of RAF-265 and mTor inhibitor (RAD001): a preclinical study”, Rome, 2011-Present, Cooperation with Università Politecnica delle Marche Principal Investigator on PD1/PDL1 evalutation in international Cooperative Group on Behalf Ca.The.Dra Foundation

PUBLICATIONS

ORIGINAL ARTICLES

1. Cortesi E, Nelli F, Mancuso A, Menichini M: “Il dolore oncologico: limiti e prospettive” Giornale Italiano di Oncologia, Vol XX-N°3/2000 page 6, CIC Edizioni Internazionali.

2. Mancuso A, Cecere FL, Cortesi E et al: “Trattamento dei pazienti con PS >2” On Oncology News N°1/2001 Pages 20-31

3. Palma M, Mancuso A, Grifalchi F, Lugini A, Pizzardi N, Cortesi E: “Case report: Atrial fibrillation during adjuvant therapy with Docetaxel”, Tumori, 88: 527-529, 2002

4. Mancuso A, Giuliani R, Palma M, Cecere FL, Cortesi E et al: ”Hepatic Arterial Continuous Infusion (HACI) of Oxaliplatin in Patients with unresectable Liver Metastases from Colorectal Cancer”, Anticancer Research 23:1917-1922, 2003 5. Cortesi E, Mancuso A et al: “I criteri di scelta per le linee successive alla prima” Educational AIOM Book Turin 28 September – 1 October 2002, pages 196-201

6. Cortesi E, Mancuso A, De Pasquale Ceratti A, De Marinis F, Beccaglia P, Bertelletti D,: “Effectiveness and Safety of a Induction therapy with Epoetin alfa in Anemic Patients Receiving Concomitant Chemotherapy”, The Oncologist, Vol 9, N°4, August 2004 7. De Marinis F, Martelli O, Mancuso A,: ”Combined Chemotherapy and Radiation in Locally Advanced Non-Small Cell Lung Cancer”, Tumori, Vol.2, No 4: S99-S102, 2003

9

8. Cortesi E, Grifalchi F, Ramponi S, Padovani A, Mancuso A, et al.: Weekly Paclitaxel and 5-Fluorouracil in Pretreated Patients with Metastatic Breast Cancer: A Phase I Study”, Anticancer Research 23: 1961-1966, 2003

9. Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E & De Marinis F: “A New Induction Schedule of Epoetin Alfa 40.000 IU in Advanced Lung Cancer Patients Treated with New Regimens Platinum Based and Suffering from Moderate to Severe Anemia”, Lung Cancer, 2004 Oct; 46(1):119-24

10. De Marinis F, Migliorino MR, Martelli O, Mancuso A,: “Update on Treatment Strategies in Advanced NSCLC” Spanish Lung Cancer Group, Fifth Congress on Lung Cancer, Barcelona, November 20-21, 2003, Educational book, pages 87-91 11. De Marinis F, Migliorino MR, Mancuso A, De Petris L, Belli R: “Neoadjuvant Strategies for Non Small Cell Lung Cancer” Tumori Vol. 3, No 2: S49-S51, 2004 12. Mancuso A, Sternberg CN: “Colorectal Cancer and Antiangiogenic Therapy: What can be expected in clinical practice?”, Crit Rev Oncol Hematol. 2005 Jul;55(1):67-81 13. Mancuso A, Sternberg CN: “New Treatments for Metastatic Kidney Cancer”, Can J Urol. 2005 Feb;12 Suppl 1:66-70 14. Mancuso A, Sternberg CN: “What’s are the news in Metastatic Kidney Cancer?”, BJU Int. 2005 Jun;95(9):1171-80 15. Mancuso A, Calabrò F, Sternberg CN, Current Therapies and Progresses in the Treatment of Pancreatic Cancer, Crit Rev Oncol Hematol., 2006 Jun;58(3):231-41 16. Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F, Correlation Between Anemia and Functional/Cognitive Capacity in Elderly Lung Cancer Patients Treated with Chemotherapy, Annals of Oncology, Ann Oncol. 2006 Jan;17(1):146-50

17. De Petris L, Migliorino MR, Ceribelli A, Martelli O, Di Molfetta M, Mancuso A, De Santis S, Di Salvia R and De Marinis F, Docetaxel Administered Every Two Weeks as Second-line Chemotherapy for Advanced Non-small Cell Lung Cancer: A Phase II Study, Anticancer Res 25(6C): 4713-4718, 2005

18. Mancuso A, Colorectal cancers and GISTs: News and Treatments, ECCO13, Continuing Education in Oncologia, ECCO 13, Vol 3 (S1), June 2006

19. Mancuso A, Sternberg CN, New Treatment Approaches in Metastatic Renal Cell Carcinoma (RCC), Curr opinion in Urology, 2006 Sep;16(5):337-41

20. Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A, Short hydration regimen and nephrotoxicity of intermediate-high dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma, Tumori, 2007 Mar-Apr;93(2):138-44

21. Mancuso A, Oudard S and Sternberg CN, Effective Chemotherapy for Hormone-Refractory Prostate Cancer (HRPC): Present Status and Perspectives with Treatments Taxanes-based, Crit Rev Oncol Hematol., 2007 Feb;61(2):176-85

10

22. Martelli O, Sacchetta S, Zivi A, Cerbone L, Garassino MA and Mancuso A, Darbepoetin Alfa Administered Every Three Weeks (Q3W) in Anemic Cancer Patients Receiving Chemotherapy (CT), Anticancer Res. 2008 May-Jun;28(3B):1767-71.

23. Perotti A, Sessa C, Noberasco C, Mancuso A, Cresta S, Carcangiu ML, Braghetti A, Scaramuzza D, Passera K, Miani M, Vigano L, Capri G, Peters B and Gianni L, An Enriched Clinical and Pharmacological Phase I evaluation of Exerin (ADH-1), A Selective Anti N-Cadherin Peptide, Ann Oncol. 2009 Apr;20(4):741-5. Epub 2009 Feb 3

24. Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V, Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis, Anticancer Res. 2009 Jul;29(7):2691-701. Review

25. Leone A, Graziano P, Gasbarra R, Paone G, Cardillo G, Mancuso A, De Marinis F, Ricciardi S, Portalone L, Pisa R, Identification of EGFR mutations in lung sarcomatoid carcinoma, Int J Cancer. 2011 Feb 1;128(3):732-5

26. Mancuso A, Sollami R, Recine F, Cerbone L, Macciomei MC, Leone A, Patient With Colorectal Cancer With Heterogeneous KRAS Molecular Status Responding to Cetuximab-Based Chemotherapy, J Clin Oncol. 2010 Sep 20. [Epub ahead of print]

27. Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D,

Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R, Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis, Lung Cancer. Lung Cancer. 2011 Jun;72(3):378-83. Epub 2010 Oct 15

28. Mancuso A, Sacchetta S, Saletti PC, Tronconi C, Milesi L, Garassino M, Martelli O, Leone A, Zivi A, Cerbone L, Recine F, Sollami R, Labianca R, Cavalli F, Sternberg CN, Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey, Anticancer Res. 2010 Oct;30(10):4289-93

29. Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi

E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A., Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations, Clin Lung Cancer. 2011 Mar;12(2):138-41. doi: 10.1016/j.cllc.2011.03.008. Epub 2011 Apr 11.

30. Graziano P, Cardillo G, Mancuso A, Paone G, Gasbarra R, De Marinis F, Leone A, Long-term

disease-free survival of a patient with synchronous bilateral lung adenocarcinoma, displaying EGFR and C-MYC molecular heterogeneity, Chest. 2011 Nov;140(5):1354-6

31. Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM,

Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G., Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from

11

acquired resistance? Ann Oncol. 2012 Mar 5. [Epub ahead of print]

32. Mancuso A., Donato De Paola E., Leone A., Catalano A., Calabrò F., Cerbone L., Zivi A., Messina C., Alonso S.,Vigna L., Caristo R. and Sternberg C.N, Translational Phase II Study of Sorafenib in Patients with Metastatic Renal Cell Carcinoma who have been Previously Treated with Anti-Angiogenic Treatment, BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x.

33. Paola ED, Alonso S, Giuliani R, Calabrò F, D'Alessio A, Regine G, Cerbone L, Bianchi L,

Mancuso A, Sperka S, Rozencweig M, Sternberg CN, An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors, Front Oncol. 2012 Nov 22;2:175. doi: 10.3389/fonc.2012.00175. eCollection 2012

34. Rozzi A, Santini D, Salerno M, Bordin F, Mancuso A, Minniti G, Nardoni C, Corona M, Falbo

PT, Recine F, Lanzetta G, Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study, Med Oncol. 2013 Mar;30(1):407. doi: 10.1007/s12032-012-0407-5. Epub 2013 Jan 10

35. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A,

Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists (Mancuso A.), Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial, Lancet Oncol. 2013 Sep;14(10):981-8

36. Ulivieri A, Cardillo G, Manente L, Paone G, Mancuso A, Vigna L, Di Stasio E, Gasbarra R, Girlando S, Leone A, Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation, Oncotarget. 2015 Aug 14;6(23):19868-79

BOOK CHAPTERS

1. Cavalli F, Cognetti F, Orecchia , Costa A, “Textbook on Medical Oncology”, Chapter XX, Sessa C, Mancuso A, Principles and Methods in Clinical Trials, 2006 2. De La Rosette J, Van Poppel H, Sternberg C, “Renal Cell Cancer”, Chapter 11.c, Sternberg C, Mancuso A, Signal Transduction Inhibitors in Renal Cell Carcinoma, 2006 3. Mancuso A, Martelli O, “Cetuximab Skin Toxicity, Handbook for patients”, On behalf AIOM Foundation and Federico Calabresi Foundation, 2006 4. Mancuso A, Sacchetta S, “Urinary Incontinence and Urinay Acute Obstruction”, On behalf AIOM Foundation, Mundipharma, 2006 5. Martelli O, Mancuso A, “skin toxicity and chemotherapy”, On behalf AIOM Foundation, Oncoform, 2008

12

6. Mancuso A, Vavalà T, “Sorafenib, new perspectives”, Cancer and Aging, Vol 6, Number 3, Suppl. 1(S1-S26), December 2008 7. Mancuso A, Recine F, Sollami R, Colorectal Cancer: Drug Therapy for Locally Advanced Disease, AIOM Guidelines, 2010 8. Mancuso A, NICSO Guidelines 2016 on Gastrointestinal Toxicities in new targeted therapies, on Behalf NICSO Faculty

WEB OR MAGAZINE EDUCATIONAL ACTIVITY

1. www.oncoforum.org (Oncoforum Faculty) 2. Research Organization Models in Oncology, Objective and strategies, MAISON Progect Il Sole 24 ore, Sanità, May 2010

ABSTRACTS 1. Martelli O, Padovani A, Mancuso A, Cortesi E et al: “Intraperitoneal Paclitaxel (IP), with paracenthesis tecnique, plus carboplatin intravenous (IV) in pretreated and non-pretreated Stage III and IV ovarian cancer patients“, Tumori, 84, (S1), N° 5 September/October 1998 2. Giuliani R, Mancuso A, Accettura C et al: “Colon Cancer post Adjuvant Therapy worthwhile”, Digestive Surgery, 17 (1): 100-101, 2000. 3. Martelli O, Padovani A, Mancuso A, Palma M, Cortesi E: “Intraperitoneal paclitaxel, with paracenthesis technique, plus carboplatin intravenous in pretreated and non-pretreated stage III and IV ovarian cancer patients”, Annals of Oncology, 11, (S2): 32, 2000.

4. Saltarelli R, Nelli F, Moscetti L, Mancuso A, Accettura C, Lugini A, D’Auria G, De Pasquale Ceratti A, Palma M and Cortesi E: “A phase I study of Vinorelbine (V) and Docetaxel (D) as second line therapy for advanced Non-Small Cell Lung Cancer (NSCLC) patients resistant to platinum/paclitaxel/gemcitabine based regimens”, III° Interregional AIOM Congress, Roma 5/7 Aprile, Abstract book, page 96 5. Moscetti L, Mancuso A, E. Cortesi et al: “A phase I study of Vinorelbine (V) and Docetaxel (D) as second line therapy for advanced Non-Small Cell Lung Cancer (NSCLC) patients resistant to platinum/paclitaxel/gemcitabine based regimens”, Annals of Oncology, 12, 2001 Suppl. 4 Ab F28

6. Cortesi E, Giuliani R, Mancuso A et al: “A feasibility study of Hepatic Arterial Infusion (HAI) with Oxaliplatin in Patients with Unresectable Liver Metastases from Colorectal Cancer (CRC)”, Annals of Oncology,12, 2001 (S4) Ab A40 7. Cortesi E, Giuliani R, Mancuso A et al: “A feasibility study of Hepatic Arterial Infusion (HAI) with Oxaliplatin in Patients with Unresectable Liver Metastases from Colorectal Cancer (CRC)”, Proc Am Soc Clin Oncol, 2001, Ab 2217

13

8. Cortesi E, Giuliani R, Mancuso A: “A feasibility study of Hepatic Arterial Infusion (HAI) with Oxaliplatin in Patients with Unresectable Liver Metastases from Colorectal Cancer (CRC)”, Roma III° Interregional AIOM Congress, Rome 5-7 April 2001, Poster Session Abstract book, page 100 9. Mancuso A, Moscetti L, Cortesi E, Palma M et al: “High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia”, 13th International Symposium MASCC /ISOO Supportive Care in Cancer Abstract and oral presentation N° 1, 2001

10. Cortesi E, Mancuso A, Moscetti L, Saltarelli R, Palma M: “High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia”. International Conference on Thrombosis and Haemostasis Issues in Cancer, Bergamo, 2-4 November 2001 11. Cortesi E, Mancuso A, Moscetti L, Saltarelli R, Palma M: “High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia”. ECCO 11, Lisbon, 20-26 October 2001, Ab 361.

12. Cortesi E, Mancuso A, Palma M, Nelli F, Cecere F: “High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia”. Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO) 2002, Vol.21, Ab 1481. 13. Moscetti L, Mancuso A, Cortesi E et al: “A phase II study of Vinorelbine (V) and Docetaxel (D) as second line therapy for advanced Non-Small Cell Lung Cancer (NSCLC) patients resistant to platinum/paclitaxel/gemcitabine based regimens”. Oslo 18th UICC, International Journal of Cancer S 13 pag 438-439 Ab N° 968 14. Mancuso A, Palma M, Cortesi E et al: ”Impact of Third Line 5-Fluorouracil-based Chemotherapy on Patients with Metastatic Colorectal Cancer”, Fourth International Conference “Perspectives in Colorectal Cancer” Barcelona June 20-22, 2002 Abstract and oral presentation N° 47 15. Mancuso A, Palma M, Cortesi E et al: ”Effects of treatment with Zoledronic Acid and Pamidronate in Normocalcemic and Metastatic bone lesions patients”, Torino AIOM Nazionale Poster G18, Annals of Oncology (S) 2002

16. Mancuso A, Palma M, Cortesi E et al: “Effects of Treatment with Zoledronic Acid in Normocalcemic and Metastatic Bone Lesions Patients”, 6° National Congress GOIM, Oral Session, Educational Book. 17. Cortesi E, Giuliani R, Mancuso A, Palma M: “A feasibility study of Hepatic Arterial Infusion (HAI) with Oxaliplatin in Patients with Unresectable Liver Metastases from Colorectal Cancer (CRC)”. Milano 4-5 Aprile 2002 Eloxatin Meeting, Abstract book, Poster/Oral Session

18. Mancuso A, Palma M, Grifalchi F, Cortesi E et al: “Early Oxaliplatin Related Neuropathy in Anemic Patients”. Oslo 18th UICC International Journal of Cancer S 13 pag 481 Ab N° 1110

19. Mancuso A, De Pasquale Ceratti A, De Marinis F, Beccaglia P, Bertelletti D, Cortesi E: “Effectiveness and Safety of a Induction therapy with Epoetin alfa in Anemic Patients Receiving Concomitant Chemotherapy” Blood Vol 100 N° 11 November 16,2002 pag. 3527

14

20. De Marinis F, Martelli O, Mancuso A, “Combined Chemotherapy and Radiation in locally advanced non-small cell lung cancer”, VII AIOM Congress, Messina May 11-14, 2003 21. Cortesi E, Grifalchi F, Mancuso A et al.: “A phase I study of weekly Paclitaxel combined with protracted continuous infusion of 5-Fluorouracil in patients with advanced breast cancer pretreated with Anthracyclines containing regimens”, Paclitaxel: present and future perspectives, Naples March 21-22, Abstract book, page 25 22. Mancuso A, Martelli O, Migliorino MR, Di Salvia R, De Marinis F: ”Impact of Third Line ZD 1839 therapy on Patient with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens (Astra Zeneca Expanded Access Programme), Abstract book, Astra Zeneca Meeting, Madrid, June 27-28, 2003 23. De Marinis F, Mancuso A, Martelli O, Migliorino MR, Di Salvia R, “Impact of fifth-line Gefitinib (‘Iressa’, ZD1839) therapy on a pretreated patient with advanced non-small-cell lung cancer”, (Astra Zeneca Expanded Access Programme), Astra Zeneca Meeting, Madrid, June 27-28, 2003, Abstract book, abstr. 4 24. De Marinis, F, Mancuso A, Martelli O, Migliorino MR, Di Salvia R: ”Impact of Third Line ZD 1839 therapy on Patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens (Astra Zeneca Expanded Access Programme), European Journal Cancer Vol I N°5 pag S240: Abstr. 798 25. De Marinis, F, Martelli O, Mancuso A: “Chemotherapy in the elderly patient with metastatic NSCLC”, INRCA/GIOGer, I stage di Oncologia Geiatrica, Hotel Villa Dominique September 16-19, 2003

26. Mancuso A, Beccaglia P, De Marinis F: “Radiochemotherapy-Associated Anemia and Survival: an Analysis of Published Studies”, Annals of Oncology Vol 14, (S4) pag iv59 abstr. E42, 2003 27. Ariganello O, Di Molfetta M, Diana F, Mancuso A, Beccaglia P, De Marinis F,: ”Effectiveness and Safety of an induction therapy With Epoetin Alfa in Lung cancer Patients Suffering From Moderate-Severe Anemia Undergoing Chemotherapy”, Annals of Oncology Vol 14, (S4) pag iv59 abstr. E43, 2003 28. Martelli O, Migliorino MR, Mancuso A, Di Salvia R and De Marinis F: ”Impact of third line Getifinib (Iressa, ZD 1839) therapy on a pretreated patient with advanced non-small cell lung cancer (NSCLC), (Astra Zeneca Expanded Access Programme), Astra Zeneca Meeting, Madrid, June 27-28, 2003, Abstract book, abstr. 2 29. Martelli O, Mancuso A, Migliorino MR, Di Salvia R & De Marinis F,: ”Impact of Third Line ZD 1839 therapy on Patients with advanced non-small cell lung cancer (NSCLC) who had failed prior platinum and/or docetaxel-based regimens” (Astra Zeneca Expanded Access Programme) Annals of Oncology Vol 14, (S4) pag iv19 abstr. B18, 2003 30. Migliorino MR, Paoluzzi L, Martelli O, Mancuso A, De Marinis F, et al., “Docetaxel (TXT) Given Ever 2 Weeks in Patients with Pretreated NSCLC” Annals of Oncology Vol 14, (S4) pag iv20 abstr. B20, 2003

15

31. De Marinis, F, Martelli O, Mancuso A: “NSCLC: Risposte che contano” Simposi AIOM, Lilly Abstract book, V° National AIOM Congress, Rome October 21-24, 2003 32. Mancuso A, Migliorino MR, Martelli O et al., “A new biweekly schedule of carboplatin and gemcitabine: phase I feasibility trial in patients with advanced Non-Small Cell Lung Cancer (NSCLC)” Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO) 2004, Vol.23, Ab 7245, pag 674 33. Migliorino MR, De Petris L, Martelli O, Mancuso A, Di Salvia R & De Marinis F, Hemoglobin increase in advanced/metastatic lung cancer patients receiving multicycle chemotherapy and darbepoetin alfa every week: An Initial Ongoing Experience, Proceedings of the Annual Meeting of American Society of Clinical Oncology (ASCO) 2004, Vol.23, Ab 8250, pag 787

34. De Petris L, Mancuso A, Migliorino MR, Martelli O, Di Salvia R and De Marinis F, Efficacy of Iressa as Third Line Treatment in NSCLC Patients. Case Series from the “Iressa Expanded Access Programme, Astra Zeneca Meeting, 2004 35. Mancuso A, Ariganello O, Di Molfetta M, Diana F, Beccaglia P, Di Salvia R, Cortesi E, De Marinis F. “Epoetin Alfa 40.000 IU in advanced/metastatic lung cancer patients suffering from moderate-severe anemia undergoing chemotherapy: A new induction schedule”, Tumori, Volume 3, N°4: S18-S20, 2004 36. Mancuso A, Migliorino MR, Martelli O, Belli R, Di Molfetta M, De Petris L, Di Salvia R, De Marinis F, “Phase I feasibility trial on a biweekly schedule of carboplatin and gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer”, Annals of Oncology (S), 2004 37. De Petris L, Migliorino MR, Ceribelli A, Martelli O, Mancuso A, Di Salvia R, Di Molfetta M, Cipri A, Ariganello O, De Marinis F, “Phase II study on biweekly docetaxel as second line chemotherapy for NSCLC patients”, Annals of Oncology (S), 2004

38. Migliorino MR, De Petris L, Martelli O, Mancuso A, Di Salvia R, De Marinis F, “Hematopoietic response in Anemic Lung Cancer Patients Receiving Weekly Darbepoetin Alfa”, Annals of Oncology Vol 15 (S2): pag ii118, Abstr N75, 2004 39. Mancuso A, Beccaglia P, De Marinis F, Correlation Between Anemia and Functional/Cognitive Capacity in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemotherapy (CT), 29th ESMO Congress, Annals of Oncology Vol 15 (S3): iii122 Abstr. 458, 2004 40. Mancuso A, Beccaglia P, Migliorino MR, De Santis S, Saponiero A, De Marinis F, Impact of Chemotherapy (CT) related Anemia on Functional/Cognitive Capacity in Elderly NSCLC Patients, J. Clin. Oncol., 2005:23(16S):772s, Abstr. 8176

41. Mancuso A, Impact of Anemia and Fatigue in cancer patients treated with chemotherapy, VII° Interregional AIOM Congress, Vasto 27-28 May 2005, AIOM Abstract book

42. Mancuso A, Beccaglia P, Migliorino MR, De Santis S, Saponiero A, De Marinis F, Impact of Chemotherapy (CT) related Anemia on Functional/Cognitive Capacity in Elderly NSCLC Patients, 11th World Conference on Lung Cancer, Barcelona, Spain, Abstr. 723

16

43. Mancuso A, Saletti PC, Sacchetta S, Romagnani E, Cavalli F, Sternberg CN, Treatment outcomes with first and second line chemotherapy in advanced and metastatic pancreatic cancer patients, J. Clin. Oncol., 2006:24, Abstr. 14107

44. Mancuso A, Saletti PC, Sacchetta S, Romagnani E, Aprile G, Fatigoni S, Garassino M, Saggese M, Cavalli F, Sternberg CN, The Efficacy of Fluoropyrimidine-based Second Line Chemotherapy in Advanced and Metastatic Pancreatic Cancer: Results of an Ongoing Retrospective Multicenter Study, World Congress on Gastrointestinal Cancer, Barcellona, Annals of Oncology Vol 17 (S6), pag D61, Abstr. 123, 2006 45. Sessa C, Perotti C, Mancuso A, Maur M, Fasolo A, Scaramuzza D, Braghetti A, Marsoni S, Malik R, Peters WP, and Gianni L., An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (N-cad) cyclic competitive binder ExherinTM (ADH-1) in patients with solid tumors, First International Meeting on "Targeted Therapies in Cancer: Myth or Reality?", Nerviano Medical Sciences, Abstract Book, September 2006

46. Mancuso A, Saletti P, Tronconi MC, Aprile G, Milesi L, Aglione S, Fatigoni S, Garassino M, Labianca R, Sternberg CN, The Efficacy of Fluoropyrimidine-based Second Line Chemotherapy in Advanced and Metastatic Pancreatic Cancer: Results of an ongoing Italian/Swiss Multicenter Survey, 31st ESMO Congress, Annals of Oncology Vol 17 (9), pag ix323, Abstr. 1131P, 2006

47. Garassino MC, Bettini A, Rossello R, Saggia C, Aglione S, Paleari D, Martelli O, Collovà E, Maggese M, Cazzaniga M and Mancuso A, Histopathological presentation of breast cancer (BC) in male patients (pts): a multicenter retrospective study, 31st ESMO Congress, Annals of Oncology Vol 17 (9), pag ix104-105, Abstr. 285P, 2006

48. Sacchetta S, Mancuso A, Calabrò F, Sternberg C.N., "Effects of Darbepoetin α administered every three weeks (Q 3 wks) on hemoglobin and fatigue in cancer patients receiving chemotherapy", VIII AIOM National Congress, Annals of Oncology Vol 17 (S11), pag xi68, Abstr. H15, 2006

49. Mancuso A, Sacchetta S, Tronconi C, Aprile G, Aglione S, Fatigoni S, Garassino MC, Saggese M, Martelli O, Saggia C, Sternberg C.N., The Efficacy of Fluoropyrimidine-based Second Line Chemotherapy in Advanced and Metastatic Pancreatic Cancer: Results of an ongoing Italian Multicenter Survey, VIII AIOM National Congress, Annals of Oncology Vol 17 (11), pag xi51, Abstr. E9, 2006 50. Ghidini A, Cazzaniga ME, Adamo B, Mancuso A, Bettini AC, Martelli O, Carta AM, Garassino M, Collovà E, Aglione S, Saggese M, Tumour characteristics and adjuvant treatment in young women (<35 years) with early breast cancer (EBC): A multicenter retrospective study, Annals of Oncology Vol 17 (11), VIII AIOM National Congress, pag xi7, Abstr. A11, 2006 51. Garassino MC, Bettini A, Rossello R, Saggia C, Aglione S, Paleari D, Martelli O, Collovà E, Maggese M, Cazzaniga M and Mancuso A, Histopathological presentation of breast cancer (BC) in male patients (pts): a multicenter retrospective study, VIII AIOM National Congress, Annals of Oncology Vol 17 (11), pag xi6, Abstr. A7, 2006 52. Aglione S, Cinquini M, Mancuso A, Borgonovo K, Petrelli F, Sergi C, Paleari D, Fatigoni S, Sdrobolini A, Martelli O, The Efficacy of Second Line Chemotherapy (CHT) in Platinum-Sensitive

17

Advanced/Metastatic small cell lung cancer (SCLC) patients: Results of on Ongoing Italian Multicenter Survey, J. Clin. Oncol., ASCO, 2007 53. Mancuso A, Sacchetta S, Saletti P.C, Tronconi C, Milesi, L, Garassino MC, Martelli O, Labianca R, Cavalli F, Sternberg C.N, Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: Results of an Italian/Swiss Multicenter Survey, J. Clin. Oncol., ASCO 2007 54. Perotti A, Mancuso A, Maur M, Fasolo A, Scaramuzza D, Braghetti A, Marsoni S, Malik R, Peters WP, Gianni L, Final results of the phase Ib/II study of the N-cadherin (N-cad) antagonist ADH-1 in patients with solid tumors, 5th International Symposium on Targeted Anticancer therapies, 2007, selected for oral presentation, Abstr number 41, abstract code O204 55. Mancuso A, Sacchetta S, Sternberg CN, DNA repair by ERCC1 in pancreatic cancer and platinum salts-based salvage chemotherapy, 5th International Symposium on Targeted Anticancer therapies, 2007, Abstr. number 29, abstract code P705

56. Mancuso A, Saletti PC, Tronconi C., Milesi, L., Garassino MC., Labianca R., Cavalli F, Sternberg C.N, DNA repair by ERCC1 in pancreatic cancer and platinum salts-based salvage chemotherapy, Molecular Mechanism Implemented in Clinical Practice Session, Abstr No 98 PD, ECLU conference, Lugano, 2007

57. Mancuso A., Leone A., Vigna L., Calabrò F., Giuliani R., De Marco S., D’Alessio A., Gasbarra R., Pisa R. and Sternberg CN, EGFR, DCC and K-RAS mutations as predictive factors for cetuximab sensitivity in metastatic colorectal cancer (mCRC), J. Clin. Oncol., ASCO 2008 58. Martelli O , Farina G, Garassino MC, Mancuso A, Gambacorta M, Gherardi G, Bianchi F, Floriani I, Torri V, Scanni A, Role of k-ras mutations in patients affected with NSCLC and treated with tyrosine kinase inhibitors (tkis): results of a pooled analysis, J. Clin. Oncol., ASCO 2008

59. Mancuso A, Leone A, Sacchetta S, Cerbone L, Garassino MC, Martelli O, Molecular Profiling in Responding and Long Survivor NSCLC Patients Treated with Second-Line Pemetrexed, First Lung Conference, ESMO, 2008 60. Mancuso A, Leone A, cerbone l, Zivi A, Squilloni E, Bertagnolio F, Caristo R, Gasbarra R, Pisa R, Sternberg C, Role of EGFR, DCC and K-RAS mutations in metastatic colorectal cancer (mCRC) patients treated with Cetuximab, TAT 2008

61. M. C. Garassino, G. Michetti, M. Lo Dico, R. Califano, S. Aglione, K. Borgonovo, A. Mancuso, D. Galetta, E. Gallerani, E. Collovà, V. Torri, Outcomes of Small Cell Lung Cancer (SCLC) patients treated with second-line chemotherapy (SL): a retrospective analysis of 166 patients, ASCO 2009

62. A. P. Mancuso, E. Donato De Paola, A. Catalano, F. Calabrò, C. Messina, A. Zivi, L. Cerbone, L. Vigna, R. Caristo, C. N. Sternberg, Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI anti-angiogenic treatment, ASCO 2009

63. M. C. Garassino, G. Michetti, M. Lo Dico, R. Califano, S. Aglione, K. Borgonovo, A. Mancuso, D. Galetta, E. Gallerani, E. Collovà, V. Torri, Outcomes of Small Cell Lung Cancer

18

(SCLC) patients treated with second-line chemotherapy (SL): a retrospective analysis of 166 patients, ECMTO, 2009 64. A. Passaro, I. Pavese, G. Lanzetta, C. Di Fonzo, A. Mancuso, W. Gianni, G.P. Spinelli, R. Madaio, A. Lembo, O. Martelli, Cancer Pain Management in Oncological Setting. The Role of Oxycodone: A New Option Starting Strategy Therapy?, ESMO 2010, Annals of Oncology 21 (Supplement 8): viii363–viii367, 2010 doi:10.1093/annonc/mdq532 65. Lanzetta G, Passaro A, Mazzoli M, Pavese I, Restuccia MR, Di Fonzo C, Pacetti U, Recine F, Mancuso A, Gianni W, Spinelli GP, Madaio R., Lembo A, Cristina G, Martelli O, Cancer Pain Management in Oncological Setting: The role of Oxycodone: A New Option Starting Strategy Therapy, Tumori, Vol 10, N°1 October 2010 66. Pavese I, Satta F, Fabbri MA, Burattini E, Todi F, Coiro G, Palombo B, Alimonti A, Mancuso A, Capuano G, Di Palma M, Telemedicine Monitoring of Oral Chemotherapy Treatment in Cancer Patients, Tumori, Vol 10, N°1 October 2010

67. Rulli E, Marabese M, Copreni E, Garassino MC, Martelli O, Broggini M, Gherardi G, Veronese S, Floriani I, Longo F, Pavese I, Labianca R, Moscetti L, Bertolini A, Cortesi E, Mancuso A, Farina G, Scanni A, on behalf of the TAILOR investigators, Different K-RAS Mutations Confer Different Drug Sensitivity in Non-Small-Cell-Lung Cancer (NSCLC), Tumori, Vol 10, N°1 October 2010 68. Pavese I, Satta F, Fabbri MA, Burattini E, Todi F, Coiro G, Palombo B, Alimonti A, Mancuso A, Capuano G, Di Palma M, Etoposide, Estramustine and PSA Response in previously treated Hormone Refractory Prostate Cancer Patients (HRPC), Tumori, Vol 10, N°1 October 2010

69. A. Rozzi, A Mancuso, F. Recine, C. Nardoni, M. Corona, M. R. Restuccia, M. Salerno, F. Bordin, T. Falbo, G. Lanzetta, Topoisomerase II and chemosensitivity for pegylated liposomal doxorubicin (pld) used in the third-line treatment of patients with metastatic bladder cancer, J Clin Oncol 29: 2011 (suppl; abstr e15055)

70. Ulivieri A, Cardillo G, Mancuso A and A Leone, Analysis of BRAF, NRAS, cKIT and EGFR alterations in melanoma lung metastases, J Clin Oncol 30: 2012 (suppl; abstr e19033)

71. Varchetta V, Montagnese F, Sibio S, Sica G, Muscaritoli M, Soda G, Giordano G, Brandi R, Tarsi, S, Mancuso G and Mancuso A; Villa Margherita Cancer Center, Rome, Italy, PD-1/PD-L1 Expression and Regorafenib Clinical Efficacy on Refractory Pancreatic Cancer Patient, ASCO 2016, Abstract #164325

SELECTED ORAL PRESENTATION AT NATIONAL OR INTERNATIONAL CONFERENCES

- Invitation to serve as Guest Speaker at the International ‘Iressa’ Clinical Experience Meeting, Madrid, June 27-28, 2003

19

- Invitation as Speaker in the Poster Symposium “Geiatric Oncology and Supportive Care” at 29th ESMO Congress, Vienna, November 1, 2004

- Invitation to serve as Guest Speaker at Young Oncologist First Educational Course (AIOM), ”Iressa Clinical and Molecular Impact in the treatment of NSCLC”, Roma, November 18, 2005

- Invitation to serve as Guest Speaker at 31st ESMO Congress “The Efficacy of Fluoropyrimidine-based Second Line Chemotherapy in Advanced and Metastatic Pancreatic Cancer: Results of an ongoing Italian/Swiss Multicenter Survey”, 29 September – 3 October 2006, Istambul, Turkey - Invitation to serve as Guest Speaker at 9th World Congress on Gastrointestinal Cancer, New trial designs with targeted therapies, June 2007, Barcelona, Spain,

- Invitation to serve as Guest Speaker at ESMO Meeting (ECLU, Lugano, 2007), DNA repair by ERCC1 in pancreatic cancer and platinum salts-based salvage chemotherapy

- Invitation to serve as Guest Speaker at ESMO Meeting (ECLU, Lugano, 2008), Highlights in genitourinary tumors - Invitation to serve as Guest Speaker at Best of Year, regional AIOM, 2009 - Invitation to serve as Guest Speaker at SIURO International Meeting, Rome, May 2010-2011 and 2012 - Invitation to serve as Guest Speaker at Lung cancer Regional Meeting, Predictive and Prognostic Factors during a therapy with Docetaxel Rome, 2010 - Invitation to serve as Guest speaker: Meet the expert: Colorectal cancer Treatment choices in borderline resectable patients: a multidisciplinary approach, October 2011 - Invitation to serve as Guest Speaker: Meet the Experts-Hot topics in colorectal cancer”, Rome, April 2011

MODERATIONS AT NATIONAL OR INTERNATIONAL CONFERENCES

- Chair during the session “Prognostic factors in colorectal cancer”, VIII° National AIOM Congress, Milan, November 17-21, 2006

- Chair during the gastrointestinal session “Comments on ASCO 2007, AIOM young regional meeting”, Rome, July 6, 2007

- Chair during ESMO Meeting (ECLU, Lugano, 2008), Highlights in genitourinary tumors, Lugano, 3-6 July 2008

20

- Chair during the lung cancer session “Comments on ASCO 2008, AIOM young regional meeting”, Rome, July 13, 2008 - Chair diring Highlights in kidney cancer, Oncoforum Conference, Amsterdam, October, 2010

- MDV3100 in prostate cancer, Advisory Board meeting ESMO, Milan, October 2010 - Co-Chair during Qtenza Advisory Board, Astellas Europe, Zurigo, Novembre 2011

- Chair during Oncoforum Summary Meeting on renal cancer, Amsterdam Nov, 2011

SCIENTIFIC DIRECTOR AT NATIONAL OR INTERNATIONAL CONFERENCES

- Director of the Conference: EGFR inhibitors and ideal combination platforms, Rome, November 2008

- Director of the Conference: mTor inhibitors and synergistic molecular Platforms, Rome, November 2009

- Co-Chair and Scientific director of molecular meeting in GI and Thorax Cancer, San Camillo/Forlanini Hospitals, Rome, 2009

- Director of the Conference: Translational Medicine in Clinical Practice, Rome, April, 2011

- Director of the Conference: Translational Medicine in Clinical Practice, Rome, May, 2013

- Director of the Conference: Translational Medicine in Clinical Practice, Rome, June, 2015

- Director of the Conference: Translational Medicine in Lung Cancer, Rome, November, 2017

EXTRA MEDICAL EMPLOYMENTS

Board Member of ASSOMEDICO, Fondazione ONLUS, Previasme, www.assomedico.it, September, 2010-present PROFESSIONAL MEMBERSHIPS

National and International Member of Thoracic Oncology Association, 2007- present

Member of American Chemical Society, 2007-present

21

Member of MaiS.O.N. Working group, 2007-present

Active Member of American Association for Cancer Research (AACR), 2005-present

Active Member of New York Academy of Sciences, 2005-present

Member of European Society Medical Oncology (ESMO), 2003-present

Active Member of American Society of Clinical Oncology (ASCO, Associate), 2003-present

Member of European School of Oncology, 2003-present

Faculty Member of Oncoforum Programme, 2007-present

Member of Italian Association of Medical Oncology, 2002-present

Member of Italian North West Oncology Group (GONO), 2001-present

Member of GISCAD Group, 2001-present

Member of CIPOMO Working Group, 2008-present

Member of Oncological Network, Supportive care guidelines, Regione Lazio, 2011-present

Roma 28/01/2017